Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
This study will investigate the use of far infrared radiation for control, management and treatment of HD.
| Condition | Intervention | Phase |
|---|---|---|
|
Huntington Disease |
Radiation: Far Infrared Radiation |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD |
- Treatment of people with HD [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Rehabilitation of people with HD [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 5 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
|
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)
|
Detailed Description:
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- People with HD
Exclusion Criteria:
- None
Contacts and Locations| Canada, Ontario | |
| The Centre for Incurable Diseases | |
| Toronto, Ontario, Canada, M4V 1L5 | |
| Principal Investigator: | Ken Nedd, M.D. | GAAD Medical Research Institute Inc. |
More Information
No publications provided
| Responsible Party: | Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc. |
| ClinicalTrials.gov Identifier: | NCT00675077 History of Changes |
| Other Study ID Numbers: | GAAD-HD-CTP1 |
| Study First Received: | May 6, 2008 |
| Last Updated: | January 2, 2009 |
| Health Authority: | Canada: Health Canada |
Keywords provided by GAAD Medical Research Institute Inc.:
|
Akinetic-Rigid Variant of Huntington Disease Chorea, Chronic Progressive Hereditary (Huntington) Chronic Progressive Hereditary Chorea (Huntington) Huntington Chorea |
Huntington Chronic Progressive Hereditary Chorea Huntington Disease, Akinetic-Rigid Variant Huntington Disease, Juvenile Huntington Disease, Juvenile-Onset |
Additional relevant MeSH terms:
|
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Dementia Chorea Dyskinesias |
Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Cognition Disorders Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013